China Biologic Products Holdings, Inc. operates as a biopharmaceutical company. The company researches, develops, and produces human plasma-based pharmaceutical and coagulation factor products in the form of tablets, injections, capsules, and syrups.
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of China Biologic Products Holdings, Inc. In connection with the proposed acquisition of the Company by Chinese investment firm CITIC Capital Holdings Ltd. Under the terms of the acquisition agreement, CBPO shareholders will receive $110 in cash for each share they own.
WeissLaw is investigating whether CBPO’s Board acted to maximize shareholder value prior to entering into the agreement. Notably, the per-share offer price is nearly $5.00 less than the Company’s 52-week high of $114.82, and $22.00 less than the analyst target price of $132.00 per share.
WeissLaw LLP: WeissLaw LLP Investigates China Biologic Products Holdings, Inc., 18 Jun 2018
China Biologic Products: Annual Report, 08 Feb 2017